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The rampant spread of antibiotic resistant bacteria has spurred interest in alternative
strategies for developing next-generation antibacterial therapies. As such, there has
been growing interest in cationic antimicrobial peptides (CAMPs) and their therapeutic
applications. Modification of CAMPs via conjugation to auxiliary compounds, including
small molecule drugs, is a new approach to developing effective, broad-spectrum
antibacterial agents with novel physicochemical properties and versatile antibacterial
mechanisms. Here, we’ve explored design parameters for engineering CAMPs conjugated
to small molecules with favorable physicochemical and antibacterial properties by
covalently affixing a fluoroquinolone antibiotic, levofloxacin, to the ten-residue CAMP
Pep-4. Relative to the unmodified Pep-4, the conjugate was found to demonstrate
substantially increased antibacterial potency under high salt concentrations. Historically,
it has been observed that most CAMPs lose antibacterial effectiveness in such high
ionic strength environments, a fact that has presented a challenge to their development
as therapeutics. Physicochemical studies revealed that P4LC was more hydrophobic
than Pep-4, while mechanistic findings indicated that the conjugate was more effective
at disrupting bacterial membrane integrity. Although the inherent antibacterial effect of
the incorporated levofloxacin molecules did not appear to be substantially realized in
this conjugate, these findings nevertheless suggest that covalent attachment of small
molecule antibiotics with favorable physicochemical properties to CAMPs could be a
promising strategy for enhancing peptide performance and overall therapeutic potential.
These results have broader applicability to the development of future CAMP-antibiotic
conjugates for potential therapeutic applications.
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INTRODUCTION
The emergence and spread of bacterial resistance to conventional
antibiotics has resulted in interest in cationic antimicrobial pep-
tides (CAMPs) as a potential therapeutic alternative (Gordon
et al., 2005; Seo et al., 2012). These peptides demonstrate broad-
spectrum antimicrobial activity and are essential elements of
innate immunity in higher organisms. Yet, despite their extensive
use in nature, bacteria have failed to develop wide-spread resis-
tance to CAMPs, which has not been the case for conventional
antibiotics (Zasloff, 2002). While CAMPs demonstrate exten-
sive sequence and structural diversity, they are generally rich in
cationic amino acids and adopt amphipathic structures that result
in spatial partitioning of basic and hydrophobic residues. These
peptides are thought to exert their antibacterial effect via mecha-
nisms that at some level involve the targeting of anionic bacterial
membranes through non-specific electrostatic and hydrophobic
interactions. Many CAMPs are thought to also bind bacterial
receptors and enzymes, or otherwise interfere with essential cel-
lular processes (Epand and Vogel, 1999; Brogden, 2005; Jenssen
et al., 2006).
While CAMPs represent a promising class of prospective
therapeutics, their development as viable treatments has proven
challenging, with one major factor being that the effectiveness of
many CAMPs are diminished or even abolished under salt con-
centrations consistent with physiologically relevant environments
(Park et al., 2004; Yu et al., 2011; Chu et al., 2013). Researchers
have investigated various strategies, including conjugation to aux-
iliary compounds, in order to enhance CAMP antibacterial per-
formance and potential therapeutic utility (Arnusch et al., 2012;
Devocelle, 2012). Conjugation is an appealing strategy because it
provides a means for introducing new functionalities and directly
enhancing CAMP antibacterial activity. For example, CAMPs
have been conjugated to fatty acids (Li et al., 2013), sugars (Pal
et al., 2011), pheromones, antibodies, synthetic polymers, and
small molecule drugs to yield peptide constructs with improved
antibacterial activity relative to their respective unmodified par-
ent peptide variants (Devocelle, 2012). However, while conjuga-
tion can improve the performance of CAMPs, it has also been
shown in some instances to abrogate antibacterial effectiveness
(Chu-Kung et al., 2004; Radzishevsky et al., 2005). Therefore, the
effect that conjugation may have on CAMP structure and physic-
ochemical properties (e.g., charge, hydropathy, and sterics, etc.)
must be considered when engineering constructs. Conjugation
of CAMPs to small molecules with favorable physicochemical
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properties (such as hydrophobic and/or cationic functionali-
ties) would provide a highly controlled means for augmenting
peptide antibacterial performance. The incorporation of small
molecule antibiotics in CAMP-based conjugates presents a par-
ticularly intriguing strategy, as these compounds could influence
peptide effectiveness not only via alteration of physicochemical
properties, but also through their intrinsic antibacterial activities.
In this regard, fluoroquinolone antibiotics, which present both
hydrophobic (e.g., aromatic and aliphatic moieties) and cationic
functionalities, represent attractive candidates. Additionally, from
a synthetic perspective, the carboxylate moieities that fluoro-
quinolones contain lend themselves to ready conjugation with
CAMP primary amino groups.
In our previous studies, we found that Pep-4, a highly
cationic peptide with a sequence (RGRRSSRRKK-NH2) based
on the C-terminal portion of human beta defensin-3 (hBD-3),
retained significant antibacterial activity following acetylation of
its N-terminal and side chain amino groups, despite the associ-
ated reduction in charge from +8 to +5 (Papanastasiou et al.,
2009). These results suggest that this peptide is amenable to
chemical modification and may be a good candidate for incorpo-
ration in CAMP-conjugates. Additionally, the sequence of Pep-4
provides a limited number of reactive functionalities, allowing
convenient chemical modification with small molecules while
reducing the potential for deleterious side reactions and byprod-
ucts. These qualities also facilitate isolation and characterization.
Moreover, the small size of Pep-4 makes it especially appealing
for use in CAMP-conjugates, as it lends itself to cost effective
synthesis (Seo et al., 2012).
In order to explore design parameters for engineering
antibacterial CAMP-conjugates and the incorporation of small
molecules, such as antibiotics, we have synthesized a CAMP-
conjugate consisting of a fluoroquinolone, levofloxacin (LVFX),
covalently attached to the scaffold peptide Pep-4 via the primary
amino groups present in the peptide. These studies have focused
on evaluating the antibacterial performance of the Pep-4-LVFX
Conjugate, P4LC, against the model gram-negative bacterium
E. coli and gram-positive bacterium B. cereus. Our studies reveal
that incorporation of LVFX significantly enhances the effective-
ness of the conjugate under physiologically relevant environmen-
tal salt concentrations relative to the unmodified scaffold peptide
Pep-4. These findings suggest that conjugation of CAMPs to aux-
iliary compounds, such as small molecule antibiotics with favor-
able physicochemical properties, to generate hybrid constructs
could be a promising strategy for enhancing peptide therapeutic
potential.
MATERIALS AND METHODS
Levofloxacin (LVFX), N-methylmorpholine (NMM) and
resazurin were purchased from Sigma-Aldrich, Co. LLC (St.
Louis, MO, USA). Bicinchoninic acid (BCA) and SYTOX Green
were purchased from ThermoFisher Scientific, Inc. (Waltham,
MA, USA). Fluoro-N,N,N′,N′-tetramethylformamidinium hex-
afluorophosphate (TFFH) was purchased from EMDMillipore (a
division of Merck KGaA; Darmstadt, Germany), Fmoc-Gly-Wang
resin from Peptides International, Inc. (Louisville, KY, USA), and
DiSC(3)5 from Anaspec, Inc. (Fremont, CA, USA). Deionized
water (dH2O) was prepared using a Milli-Q Synthesis A10
system (Millipore). The bacterial strains E. coli (#25922) and
B. cereus (#11778) were purchased from American Type Culture
Collection (ATCC, Manassas, VA, USA). Pep-4 (≥95% purity)
was custom synthesized by Genscript USA, Inc. (Piscataway, NJ,
USA). Melittin (≥95%) was purchased from Anaspec, Inc., and
indolicidin was synthesized (≥95% purity) by AAPPTec, LLC
(Louisville, KY, USA). Peptide identities were verified via matrix
assisted laser desorption ionization time-of-flight (MALDI-TOF)
mass spectrometry using a Shimadzu AXIMA Performance.
Additionally, Pep-4 and the conjugate were submitted for amino
acid analysis (UC Davis Genome Center Proteomics Core
Facility) in order to establish molar concentrations.
P4LC SYNTHESIS AND PURIFICATION
The carboxyl group of LVFX allowed for conjugation to Pep-4 via
direct acylation of the peptide’s N-terminal and lysine side chain
amino groups. LVFX was preactivated by converting its carboxyl
moiety into an acyl fluoride in order to facilitate nucleophilic
attack by peptide amino groups. Equimolar amounts of LVFX
(6.7mg, 18.6mmol) and TFFH (4.90mg, 18.6mmol) were dis-
solved in 500μL of anhydrous DMF, and 20μL of NMM was
then added to the solution. This reaction was allowed to stir at
room temperature (rt), under N2 in the dark. After 1 h, Pep-
4 (2.4mg, 1.86mmol) dissolved in 200μL of anhydrous DMF
was added to the reaction and allowed to continue stirring at rt,
under N2 in the dark. While the coupling reaction was stirring,
Fmoc-Glycine-Wang resin (200mg, 0.63mmol/g amine loading)
was suspended in 8mL of DMF with agitation for 30min to
swell the resin, and the solvent was then removed via vacuum
filtration. The suspension and filtration process was repeated.
The swelled resin was then suspended in 8mL of 50% piperi-
dine in DMF for 30min in order to remove the Fmoc protecting
group. The reaction mixture was vacuum filtered and the resin
resuspended in 8mL of DMF and agitated for 15min. The resin
suspension was then vacuum filtered, and the deprotected par-
ticles were transferred to the reaction vessel. Following addition
of the resin, the reaction was left stirring in the dark under N2,
overnight. Thereafter, the contents of the reaction vessel were fil-
tered through a course frit directly into cold diethyl ether, and
the resulting suspension was centrifuged so as to pellet the pre-
cipitated material. The pelleted precipitate was then dried under
vacuum in order to remove residual ether. Crude conjugate was
subsequently dissolved in 10mL of 10mM NaCl and dialyzed
(0.5–1 kD Mw cutoff) in 10mL 10mM NaCl against 2 L dH2O,
which was replaced every 8 h (3x). The dialyzed solution was then
lyophilized to yield 3.1mg of purified P4LC (∼87% yield).
MASS SPECTROMETRY
Samples dissolved in dH2O (1 pmol/μL) were mixed with
α-cyano-4-hydroxycinnamic acid (CHCA) matrix solution
(10mg/ml in 50:50 water/acetonitrile with 0.1% TFA) and
deposited onto a stainless steel target plate (Shimadzu Kratos
Analytical) in 1μL aliquots. Mass spectra were collected using a
Shimadzu AXIMA Performance MALDI-TOF mass spectrom-
eter equipped with a 337 nm N2 laser in reflectron mode and
represent the average of at least 50 accumulated profiles. The
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laser repetition rate was set to 50Hz, and laser power was set to
between 50 and 70%. The instrument was externally calibrated
using angiotensin II, angiotensin I, and Adrenocorticotropin
hormone (fragment 18–39). Lower molecular weight regions of
spectra were assessed with the ion gate turned off, and control
spectra were generated for matrix alone. CHCA peaks were used
for internal calibration of the lower molecular weight regions of
sample spectra. Matrix m/z values were verified using MassBank
Mass Spectral Database (Accession: MCH00005).
ANTIBACTERIAL PERFORMANCE ASSAYS
The antibacterial activities of P4LC, Pep-4, LVFX, and free Pep-4
in combination with free LVFX (Pep-4/LVFX) were determined
in a microplate-based assay using resazurin as an indicator for cell
viability. Metabolically active cells convert resazurin, which is not
fluorescent, to the highly fluorescent resorufin (530/590 nmem),
and the rate of this conversion provides a means for quantifying
the concentration of viable bacteria (Shiloh et al., 1997; Lemos
and Carareto-Alves, 1998; Okuda et al., 2006; Mariscal et al.,
2009). In order to assess the effect environmental ionic strength
had on antibacterial effectiveness, assays were conducted in
buffers with the following ionic strengths: 26mM, 111mM, and
167mM.
Frozen enumerated aliquots of bacteria were thawed and
diluted into sterile buffer to a bacterial concentration of 2 ×
106 CFU/mL. Wells of a 96-well polypropylene microtiter plate
(Greiner Bio-One) were charged with 50μL aliquots of buffer
solutions containing serially diluted peptide, conjugate, or drug
followed by 50μL aliquots of diluted bacterial cells. Assays for
each compound were prepared in triplicate. Control wells were
prepared where the peptide/conjugate/drug solution was replaced
with an equal volume of buffer alone. Following addition of bac-
teria, the microtiter plates were incubated for 3 h at either 37◦C
(E. coli) or 30◦C (B. cereus). Aliquots of PBS solution (100μL)
containing resazurin and MHB were then added to each well
to afford final concentrations of 100μM resazurin and 0.2%
MHB (wt/vol) for E. coli and 12.5μM resazurin and 0.05%MHB
(wt/vol) for B. cereus. Plates were then immediately placed in a
SpectraMax Gemini EM plate-reading fluorometer for overnight
monitoring of fluorescence (530 nmex/590 nmem) at either 37◦C
(E. coli) or 30◦C (B. cereus) with intermittent shaking. Onset
time of half maximal fluorescence (T0.5) observed for each well
was computed using the microplate data analysis software. In
order to determine bacterial survival, it was necessary to estab-
lish correlations between bacterial concentration (CFU/mL) and
T0.5 values. Therefore, standard curve equations were generated
in preliminary experiments using bacterial suspensions serially
diluted (∼106 CFU/mL—103 CFU/mL) in each of the three
buffers used in the antibacterial assays. Plotting initial bacterial
concentrations (determined via dilution plating onto MHB Agar
plates) against observed T0.5 values afforded equations 1 (E. coli)
and 2 (B. cereus), which were used to interpolate viable bacte-
rial concentration (CFU/mL) following incubation with peptide,
conjugate or drug. The Y-intercept (Yint) values for equations
generated for the varied ionic strength buffer conditions were 9.41
(26mM), 9.19 (111mM), and 9.24 (167mM) for E. coli, and 5.91
(26mM), 6.20 (111mM), and 6.36 (167mM) for B. cereus.
log (CFU/mLE.coli) = −2.00 × 10−4(T0.5) + Yint (1)
log (CFU/mLB.cereus) = −1.00 × 10−4(T0.5) + Yint (2)
Antibacterial effectiveness against each microbe was determined
by plotting bacterial survival as a function of the log of the con-
centration of P4LC, Pep-4, LVFX, or Pep-4/LVFX, and fitting
the resulting data to a variable-slope sigmoidal regression model
(equation 3) using Graphpad Prism 5 (GraphPad Software, Inc.).
In this equation, log(EC50) represents the log of the concentra-
tion of P4LC, Pep-4, LVFX, or Pep-4/LVFX required to kill half of
the bacterial population, where Smin and Smax correspond to the
minimal andmaximal bacterial survival values (respectively), and
HS is the parameter defining the steepness of the transition slopes
of sigmoidal survival curves.
Bacterial Survival = Smin + (Smax − Smin)/
(1 + 10log(EC50)−log(PC)∗HS) (3)
Best-fit log (EC50) values generated for each compound were
used to compare the antibacterial effectiveness of P4LC, Pep-4,
LVFX, and Pep-4/LVFX against each bacterium. Antilogs of the
log (EC50) values, the EC50 values, are tabulated in Table 1 along
with their respective 95% confidence intervals.
Table 1 | Antibacterial effectiveness.
P4LC Pep-4 Pep-4/LVFX LVFX
E. COLI
µ1 0.0167 (0.0132–0.0230) 0.0168 (0.0123–0.0234) 0.00375 (0.00314–0.00447) 0.00281 (0.00228–0.00344)
µ2 1.71 (1.60–1.81) 28.3 (17.2–46.7) 0.00487 (0.00387–0.00617) 0.00223 (0.00164–0.00303)
µ3 1.51 (1.41–1.82) 29.4* (21.9–35.4)* 0.00404 (0.00294–0.00556) 0.00277 (0.00200–0.00385)
B. CEREUS
µ1 0.0218 (0.0156–0.0287) 0.0271 (0.0217–0.0343) 0.112 (0.0794–0.165) 0.212 (0.104–0.450)
µ2 2.17 (2.01–2.25) 178*(142–223)* 0.941 (0.645–1.27) 0.591 (0.381–0.918)
µ3 40.0 (27.3–72.0) 404* (155–462)* 1.37 (0.801–2.32) 0.981 (0.57–1.67)
Antibacterial potencies for P4LC, Pep-4, Pep-4/LVFX and LVFX expressed in terms of EC50 values (µM) and corresponding 95% confidence interval ranges. Ionic
strengths of assay media correspond to: µ1 = 26mM, µ2 = 111mM, and µ3 = 167mM.
*Estimated values are given for Pep-4 under conditions where it failed to achieve sufficient killing (within the tested peptide concentration range) to define the lower
survival boundary for fitting to Equation 3.
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DiSC (3)5 MEMBRANE DEPOLARIZATION ASSAY
Enumerated frozen aliquots of E. coli and B. cereus cells were
thawed and washed 3x with buffer (10mM NaPO4, pH 7.4).
The washed cells were diluted in 10mM NaPO4 buffer con-
taining 10 ug/mL DiSC(3)5 to afford a concentration of 4 ×
107 CFU/mL. Bacterial suspension was added to the wells of
a black polypropylene microtiter plate (Greiner Bio-One) in
100μL aliquots, and fluorescence was monitored (rt, with lid
on) using a SpectraMax Gemini EM plate-reading fluorome-
ter (622 nmex/ 670 nmem) until fluorescence quenching stabilized
and maximal DiSC(3)5 uptake was achieved. Aliquots (100μL)
of P4LC, Pep-4, LVFX, or Pep-4/LVFX were added to the bac-
teria and changes in fluorescence were monitored for 30min
with the lid off. The final concentrations of each assessed com-
pound in the wells were 33μM (P4LC and Pep-4), 126μM
(Pep-4/LVFX), and 93μM (LVFX), while final bacterial con-
centrations were 2 × 107 CFU/mL. Assays were performed in
triplicate for each compound assessed. Depolarization assays
based on DiSC(3)5 are extremely time-sensitive; therefore, trip-
licate sets for each compound were prepared simultaneously
using a multichannel pipettor. Prior experiments verified that
each tested compound was able to exert full killing under the
assay conditions. A negative control containing only bacteria
and DiSC(3)5 was used to establish background fluorescence,
while maximal membrane depolarization was established using
melittin (33μM), a known pore-forming CAMP (Lee et al.,
2013b); these controls provided references for establishing rela-
tive effectiveness of P4LC, Pep-4, LVFX, and Pep-4/LVFX. The
fluorescence kinetics data sets were normalized by setting emit-
ted fluorescence to 0 at t = 0 s and presenting fluorescence
intensity values as a fraction of maximal fluorescence observed
for melittin.
SYTOX GREEN MEMBRANE PERTURBATION ASSAY
Enumerated frozen aliquots of E. coli and B. cereus cells were
thawed and washed 3x with buffer (10mM NaPO4, pH 7.4).
The washed cells were diluted to a concentration of 4 × 107
CFU/mL in 10mM NaPO4 (pH 7.4) buffer containing 5μM
SYTOX Green, and the resulting suspension then stored in the
dark for ∼20min. The bacterial suspension was then distributed
in 100μL aliquots to wells of a black polypropylene microtiter
plate (Greiner Bio-One). Aliquots (100μL) of buffer contain-
ing P4LC, Pep-4, LVFX, or Pep-4/LVFX were then added to
wells containing cell suspension and gently mixed. The flu-
orescence of each well was immediately monitored (without
the lid) using a SpectraMax Gemini EM plate-reading fluo-
rometer (485/520 nmem). As SYTOX Green assays can be time-
sensitive, assays were prepared in triplicate using a multichan-
nel pipettor. The reported SYTOX Green data reflects observa-
tions from biological triplicates. Antibacterial assays confirmed
that each compound was able to exert full killing under these
conditions and at the concentrations used in the DiSC(3)
5 assay (33μM P4LC, 33μM Pep-4, 126μM Pep-4/LVFX,
and 93μM LVFX). A negative control containing only bac-
teria and SYTOX Green was used to determine background
fluorescence, and maximal perturbation of the bacterial cell
membranes was established using melittin. The fluorescence
kinetics data sets were normalized by setting emitted fluo-
rescence to 0 at t = 0 s and presenting fluorescence inten-
sity values as a fraction of maximal fluorescence observed for
melittin.
STATISTICAL ANALYSIS
An F test was used for determining whether log (EC50) values
generated for the assessed compounds were significantly differ-
ent from each other (computed using GraphPad Prism). For
membrane depolarization and perturbation experiments, fluores-
cence data was analyzed by comparing best-fit curves (GraphPad
Prism). Fluorescence kinetic curves were fit to a polynomial
regression model (equation 4) to allow for statistical compari-
son of the fluorescence data via an F test, with all four best-fit
parameters used as criteria.
RFU = A0 + A1(t) + A2(t)2 + A3(t)3 + A4(t)4 (4)
DISTRIBUTION COEFFICIENT
The relative hydrophobicities of P4LC, Pep-4, and LVFX were
established using a biphasic system consisting of immiscible 1-
octanol and 10mM NaPO4 (pH 7.4) to determine their respec-
tive distribution coefficients (D7.4), with D7.4 corresponding to
the concentration ratio of each compound between the octanol
and aqueous phases (Brillault et al., 2010; Cheng et al., 2012;
Chyan et al., 2014). In these experiments, P4LC, Pep-4 or free
LVFX dissolved in 100μL of 10mM NaPO4 (pH 7.4) buffer was
combined with 100μL of 1-Octanol in a 1.5mL low binding
polypropylene microcentrifuge tube (Corning). Each tube was
vortexed for 10min and the contained solvent allowed to set-
tle. Once the aqueous and octanol layers had reestablished and
fully separated, 25μL aliquots were removed from the aque-
ous phase using a micropipette, and the peptide or conjugate
concentration determined using an absorbance-based BCA kit
(Wrolstad et al., 2004). Aqueous phase Pep-4 and P4LC con-
centrations were determined via interpolation based on stan-
dard curves that had been generated using two-fold serially
diluted peptide or conjugate dissolved in 10mM NaPO4(pH
7.4). The maximal concentrations of Pep-4 and P4LC in the
calibration curves were also established using amino acid anal-
ysis (UC Davis Genome Center Proteomics Core Facility). The
results from amino acid analysis were in agreement with those
obtained using the BCA kit. The concentration of LVFX in the
aqueous layer was interpolated from calibration curves estab-
lished using absorbance at 298 nm (LVFX absorbs strongly at
this wavelength). Indolicidin and melittin were used as ref-
erence peptides in these studies. The sequence of indolicidin
suggests that it is highly hydrophobic, while that of melittin indi-
cates that it should be moderately hydrophobic. Computational
verification of the hydrophobicity of these reference peptides
was performed using the Hopp and Woods scale (Hopp and
Woods, 1981). The D7.4 values generated for P4LC, Pep-4,
LVFX, indolicidin, and melittin were calculated (equation 5)
based on their respective concentrations in the aqueous phase
([peptide]PO4buffer) of the water/octanol biphasic system and their
concentrations in the initial stock solution ([peptide]total). Values
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= log ([peptide]octanol/[peptide]PO4buffer) (5)
RESULTS
SYNTHESIS AND PURIFICATION OF Pep-4-LVFX CONJUGATE
The carboxylmoiety of LVFX allowed for conjugation to Pep-4 via
direct acylation of N-terminal and lysine side chain amino groups
on the peptide (Figure 1). LVFX was preactivated with TFFH to
convert the carboxyl moiety to an acyl fluoride prior to introduc-
tion of Pep-4. Excess activated LVFXwas captured using a glycine-
Wang resin. The resulting particle suspension was filtered through
a medium glass frit into cold ether in order to remove the resin
and precipitate the desired conjugate. The precipitated product
was dissolved in 10mM NaCl and dialyzed against deionized
water to remove water soluble, low molecular weight impurities
and byproducts. This approach was employed because removal of
intermediates and byproducts by chromatography and extraction
proved challenging and resulted in significant loss of product. The
isolated material was analyzed by MALDI-TOF mass spectrome-
try (Figure 2), which indicated the degree of drug loading to be
3:1 LVFX/peptide, with no free peptide detected. Moreover, no
intermediate conjugate species were observed. Lower molecular
weight regions of spectra from conjugate spectra were compared
to the corresponding regions in reference spectra collected for free
LVFX and matrix alone (Figure 3) in order to verify the absence
of free drug and other low molecular weight impurities.
ANTIBACTERIAL EFFECTIVENESS
The antibacterial potencies of P4LC, Pep-4, and LVFX, as well
as unmodified Pep-4 assayed in combination with free LVFX
FIGURE 1 | Pep-4 was coupled to LVFX in a two-step, one-pot synthesis. The carboxyl moiety of LVFX was preactivated using TFFH to afford the acyl
fluoride. Pep-4 was then added to the activated LVFX reaction mixture to yield P4LC.
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FIGURE 2 | MALDI-TOF mass spectrum of P4LC (m/z: 2315.5)
obtained after purification indicates a 3:1 LVFX/Pep-4 loading
stochiometry. No peaks assignable to Pep-4 or intermediately
acylated conjugate species were observed. The baseline isotopic
distribution for P4LC is shown in the inset with labeling of the
monoisotopic peak.
FIGURE 3 | Comparison of spectra at the region where LVFX m/z
should appear. The absence of any discernible peak near 362.2 in the
spectrum for P4LC (A) indicates that no LVFX contamination was present in
isolated conjugate product. Spectra for matrix alone (B) and LVFX alone
(C) are shown for comparison. As evidenced in the spectra, matrix-related
peaks did not interfere with detection of the peak assigned to LVFX.
(Pep-4/LVFX), were evaluated against the model gram-negative
and gram-positive bacteria E. coli and B. cereus, respectively.
Assays were conducted under three different ionic strength (μ)
buffer conditions in order to assess the effect salt concentration
had on antibacterial effectiveness. The lowest ionic strength buffer
used was 10mM NaPO4, pH 7.4, which corresponded to 26mM
total ionic strength. The intermediate ionic strength buffer con-
sisted of 10mM NaPO4 combined with cation-adjusted PBS in a
one to one volume ratio, which afforded a 111mM ionic strength
buffer with a pH of 7.4. Undiluted cation-adjusted PBS (pH =
7.4), with an ionic strength of 167mM, was used as the high ionic
strength buffer. Bacterial survival results were plotted against the
log of the concentration of conjugate, peptide, or free drug. EC50
values for each assessed compound were calculated by fitting the
survival data to equation 3, which models typical sigmoidal dose-
response behavior using a variable Hill slope. An F test was used to
assess statistical significance, with the alpha level set to 0.05. EC50
values and their respective 95% confidence intervals are shown in
Table 1, and generated survival curves are shown in Figure 4.
In low ionic strength conditions (μ = 26mM), P4LC demon-
strated similar antibacterial activity to Pep-4 against both bac-
teria. Against E. coli, the conjugate demonstrated an EC50 of
0.0167μM, which was not found to be significantly different
than that of the free peptide, which displayed an EC50 value
of 0.0168μM (p = 0.91). Against B. cereus, P4LC demonstrated
an EC50 value of 0.0218μM, while Pep-4 displayed an EC50 of
0.0271μM, values which were also determined not to be sig-
nificantly different (p = 0.21). The combination of free LVFX
and Pep-4 (Pep-4/LVFX) demonstrated an EC50 of 0.00375μM
against E. coli, while that of free LVFX was 0.00281μM, values
which were not significantly different from each other (p = 0.20).
Against B. cereus, Pep-4/LVFX had an EC50 of 0.112μM and free
LVFX an EC50 of 0.212μM, values which were approximately
five-fold and ten-fold greater, respectively, than those determined
for P4LC and Pep-4. The EC50 value of Pep-4/LVFX was not
significantly different than that of free LVFX alone (p = 0.36)
against B. cereus.
P4LC demonstrated EC50 values of 1.71μM and 2.17μM
against E. coli and B. cereus, respectively, in intermediate ionic
strength conditions (μ = 111mM). These values are approxi-
mately 17-fold and 82-fold lower than those of Pep-4, 28.3μM
(E. coli) and 178μM (B. cereus), under the same conditions.
Against B. cereus, Pep-4 displayed antibacterial activity only at
high peptide concentrations, killing a maximum of 69% of bac-
teria at the highest assessed peptide concentration (491μM). In
order to fit the data to Equation 3 and estimate the potency of
Pep-4, it was necessary to set the lower boundary to 0%, a con-
straint not typically imposed. Therefore, the EC50 value given
for Pep-4 against B. cereus under these conditions represents an
estimated value. P4LC, LVFX, and Pep-4/LVFX provided suffi-
cient data points in the lower survival ranges to fit the data by
setting the lower survival boundary to ≥0%. Overall, the poten-
cies of P4LC and Pep-4 decreased significantly compared to their
respective performances against both bacteria under low salt con-
ditions. Meanwhile, the potencies of Pep-4/LVFX (0.00487μM)
and free LVFX (0.00223μM) against E. coli were not signifi-
cantly affected by the increased ionic strength. However, in the
case of B. cereus, the EC50 values for Pep-4/LVFX (0.941μM)
and free LVFX (0.591μM) were significantly higher than those
observed under low ionic strength conditions. The potencies of
Pep-4/LVFX and LVFX were not found to be significantly dif-
ferent from each other for either E. coli (p = 0.071) or B. cereus
(p = 0.11) under these conditions.
Under high ionic strength conditions (μ = 167mM), the con-
jugate demonstrated EC50 values of 1.51μMand 40.0μMagainst
E. coli and B. cereus, respectively. By comparison, the EC50
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FIGURE 4 | Antibacterial effectiveness of P4LC, Pep-4, Pep-4/LVFX
and LVFX against E. coli (A,C,E) and B. cereus (B,D,F). The top row
(A,B) were generated for assays performed in low total ionic strength
(26mM), the middle row (C,D) for intermediate total ionic strength
(111mM), and the bottom row (E,F) for high total ionic strength
(167mM) conditions. Data were fit to equation 3, a standard variable
slope dose-response equation, in order to obtain EC50 values. Pep-4
failed to achieve sufficient killing (within the tested peptide
concentration range) to define the lower survival boundary for fitting to
Equation 3 under higher ionic strength conditions (D–F), and it was
necessary to set the lower boundary to 0. Curves based on the data
constraints are shown in red.
values achieved under high salt conditions with free peptide were
29.4μMagainst E. coli and 404μM against B. cereus. Thus, as was
the case in the intermediate ionic strength environment, P4LC
proved significantly more effective than Pep-4 (approximately
20-fold and 10-fold more potent against E. coli and B. cereus,
respectively). Pep-4 failed to exert full killing activity under high
ionic strengths within the range of concentrations evaluated,
killing a maximum of 90% of E. coli (highest tested peptide con-
centration was 410μM) and 56% of B cereus (highest peptide
concentration tested was 983μM). Therefore, it was necessary
to set the lower survival boundary to 0% against both bacteria
for Pep-4. The conjugate’s EC50 against E. coli did not change
significantly as a result of the ionic strength increase from 111
to 167mM, while its effectiveness against B. cereus decreased by
approximately an order of magnitude as a result of the change in
environment. This trend was similar to that observed with Pep-4,
where the peptide exhibited a substantial increase in its EC50 value
against B. cereus, though not against E. coli, as a result of the assay
ionic strength increase from 111 to 167mM. Under high ionic
strength conditions, the Pep-4/LVFX combination demonstrated
an EC50 of 0.00404μM against E. coli and free LVFX exhibited
an EC50 of 0.00277μM. The values were not found to be sig-
nificantly different from each other (p = 0.51). Moreover, their
high salt EC50 values were not significantly different from the
EC50 values that they demonstrated under intermediate ionic
strength conditions. Meanwhile, Pep-4/LVFX exhibited an EC50
of 1.37μM against B. cereus, and free LVFX showed an EC50 of
0.981μM, values that were determined to not be significantly
different from each other or the corresponding values observed
under intermediate ionic strength conditions.
MEMBRANE DISRUPTION
CAMPs have been shown to directly perturb bacterial mem-
brane integrity, with the degree of inflicted disruption varying
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depending on both the peptide and the bacteria being targeted.
CAMP-induced membrane disruption can range from the for-
mation of minor transient gaps that result in depolarization of
the membrane to the formation of larger perturbations and pores
(Kaplan et al., 2011). The degree of disruption in bacterial cell
membranes can be probed using fluorometric reporter molecules
such as DiSC(3)5 (for depolarization) (Síp et al., 1990; Zhu and
Shin, 2009) and SYTOX Green (for more substantial membrane
disruption) (Luque-Ortega et al., 2008).
The ability of P4LC, Pep-4, LVFX, and Pep-4/LVFX to depo-
larize bacterial membranes was examined using the carbocyanin
dye DiSC(3)5. When exposed to live cells, DiSC(3)5 concen-
trates in hyperpolarized membranes (Síp et al., 1990; Kaplan
et al., 2011), which results in quenching of its fluorescence
(622/670 nmem). Dissipation of membrane potential gradients
resulting from even minor transient disruptions in lipid bilayer
integrity inflicted by antibacterial agents such as CAMPs results
in the release of trapped DiSC(3)5, which can be detected by
monitoring DiSC(3)5 fluorescence (Rathinakumar et al., 2009;
Zhu and Shin, 2009). In this study, fluorescence induction curves
were generated for conjugate, peptide, or drug in the presence of
E. coli and B. cereus cells that had been charged with DiSC(3)5.
The data sets for P4LC, Pep-4, LVFX, and Pep-4/LVFX were com-
pared to that obtained for melittin (Lee et al., 2013b), a known
pore-forming CAMP that was used as a positive control to estab-
lish maximal depolarization. Data for DiSC(3)5 release was fit
to a polynomial regression model (equation 4, see Materials and
Methods) and these data were then subjected to an F test, with
the alpha level set to 0.01, in order to allow comparison of curves
and establish statistical significance of any observed similarities or
differences. Fitted curves are shown in Figures 5A,B.
Addition of P4LC to wells containing E. coli and B. cereus
led to a rapid increase in fluorescence in both cases. Compared
to the results obtained for melittin, P4LC was able to cause
53.6 and 33.5% mean maximal fluorescence against E. coli and
B. cereus, respectively. In contrast, Pep-4 caused 26.6% maximal
fluorescence against E. coli and 7% against B. cereus. Similarly,
Pep-4/LVFX induced 25% maximal fluorescence against E. coli
and 7.4% against B. cereus. Finally, free LVFX was only able to
cause 8.4% and 2.5% of maximal fluorescence against E. coli and
B. cereus, respectively. The best-fit curves generated for P4LC and
free LVFX were found to be significantly different from those of
Pep-4 and Pep-4/LVFX, as well as from each other. Meanwhile,
the curves generated for Pep-4 and for Pep-4/LVFX were found to
not be significantly different from each other (p = 0.32 for E. coli;
p = 0.071 for B. cereus).
The membrane impermeable reporter SYTOX green was used
as a probe to gain further insight into the effects of P4LC, Pep-4,
LVFX, and Pep-4/LVFX on E. coli and B. cereus cell membrane
integrity. SYTOX Green has been shown to bind DNA, which
results in a>500-fold increase in fluorescence intensity. The DNA
found in intact bacteria is inaccessible to SYTOX Green binding,
FIGURE 5 | Depolarization (top row) and perturbation (bottom
row) of E. coli membranes (A,C) and B. cereus membranes
(B,D) induced by P4LC, Pep-4, Pep-4/LVFX, LVFX and melittin.
Fluorescence values are presented as a percentage of the
maximal fluorescence signal intensities observed for the
pore-forming CAMP, melittin.
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with fluorescence occurring only after the integrity of the bacterial
membrane has been sufficiently compromised (Roth et al., 1997).
Whereas DiSC(3)5 requires only minor and transient disruption
in membrane integrity for its release from membranes, SYTOX
Green requires more substantial perturbation to enter the bacte-
rial cytoplasm and bind DNA. Accordingly, incubation of bacteria
with CAMPs that perturb membrane integrity sufficiently for
SYTOX green to enter the cytoplasm results in an increase in fluo-
rescence (Lee et al., 2013b). As with the membrane depolarization
studies described above, fluorescence curves were generated for
P4LC, Pep-4, LVFX, and Pep-4/LVFX, and the data sets compared
to those generated for melittin, which was used as the posi-
tive reference to establish maximal SYTOX Green fluorescence.
Fluorescence induction curves were fit to equation 4 for statistical
assessment (Figures 5C,D).
Addition of P4LC to wells containing E. coli led to a moder-
ate increase in fluorescence; however, no noticeable increase in
fluorescence was noted for B. cereus. In the case of E. coli, incu-
bation with P4LC resulted in 21.4% mean maximal fluorescence
relative to the results obtained for melittin. Pep-4 afforded 19.1%
maximal fluorescence against E. coli and, similar to P4LC, yielded
no noticeable fluorescence increase with B. cereus. The best-fit
curve for P4LC when incubated with E. coli was found to be sig-
nificantly different than that of Pep-4 (p < 0.0001), while the
curves for Pep-4 and P4LC against B. cereus were not found to
be significantly different (p = 0.44). Similar to P4LC and Pep-
4, Pep-4/LVFX provided approximately one fifth of the maximal
fluorescence increase when incubated with E. coli and no notice-
able increase with B. cereus. The best-fit curves for Pep-4/LVFX
were found to be significantly different than those of P4LC (p <
0.0001) for both bacteria. However, the best-fit curves for Pep-
4/LVFX were determined to not be significantly different from
those of Pep-4 (p = 0.012 for E. coli; p = 0.062 for B. cereus).
No increase in fluorescence was noted when either bacterium was
incubated with LVFX.
DISTRIBUTION COEFFICIENT
Hydrophobic moment is known to be a crucial factor influenc-
ing CAMP membrane dynamics and overall antibacterial activity
(Liu and Deber, 1998; Stark et al., 2002; Chen et al., 2007; Yin
et al., 2012; Lee et al., 2013a). In order to gain insight into
the relative hydrophobicities of P4LC, Pep-4, and LVFX, their
partitioning between aqueous 10mM NaPO4 (pH 7.4) and 1-
octanol, a non-polar solvent that is immiscible with water, was
assessed. The concentration ratios of each compound between the
two liquid phases were used to establish distribution coefficients
(D7.4). Indolicidin and melittin were used as reference peptides
in these studies. Indolicidin is a short tryptophan and proline-
rich CAMP with a high overall hydrophobicity (Podorieszach
and Huttunen-Hennelly, 2010), while melittin is a well-studied
peptide with an intermediately hydrophobic sequence (Li et al.,
2013). LogD7.4values for Pep-4, P4LC, LVFX,melittin, and indoli-
cidin are shown in Figure 6. Based on the results of these parti-
tioning studies, Pep-4 was found to be the least hydrophobic of
the CAMPs tested, demonstrating a logD7.4 of −2.57. By com-
parison, the logD7.4 of P4LC was found to be −1.65 (D7.4 =
0.0210), approximately an order of magnitude greater than that of
FIGURE 6 | Experimentally determined logD7.4 values for P4LC, Pep-4,
LVFX, melittin, and indolicidin.
Pep-4. Meanwhile, LVFX demonstrated a logD7.4 value of −1.05
(D7.4 = 0.094), which was about 4.5-fold greater than P4LC in
terms of D7.4. The reference peptide indolicidin was found to have
a logD7.4 value of 2.30, which was substantially higher than that
observed for any other compound tested. The logD7.4 value for
melittin, which was predicted to exhibit intermediate hydropho-
bicity, was determined to be −0.46, approximately an order of
magnitude greater than that of the conjugate.
DISCUSSION
These studies have focused on the antibacterial performance of
a peptide conjugate comprised of the fluoroquinolone LVFX
covalently affixed to Pep-4, a ten-residue CAMP based on the
c-terminal sequence of hBD-3. The conjugate, P4LC, was syn-
thesized via acylation of primary amino groups in Pep-4 using
the carboxyl moiety of LVFX. Our findings reveal that attachment
of LVFX to Pep-4 yields a conjugate with significantly enhanced
potency relative to the scaffold peptide in physiologically relevant
ionic strength conditions. The results observed for unmodified
Pep-4 coadministered with free LVFX suggests that the conju-
gate’s antibacterial potency is not due to extracellular release of
free drug.
The antibacterial effectiveness of P4LC, Pep-4, LVFX, and
free peptide in combination with free drug (Pep-4/LVFX) were
assessed against the model gram-negative and gram-positive bac-
teria, E. coli and B. cereus, respectively. Assays were conducted
in various ionic strength environments, including physiologically
relevant conditions, in order to evaluate the effect that salt con-
centration had on their antibacterial potencies. While P4LC and
Pep-4 did not demonstrate significantly different EC50 values
against either bacterium in the lowest ionic strength conditions
tested (μ = 26mM), the conjugate was found to be substantially
more effective than the free peptide at higher ionic strengths.
At an ionic strength of 111mM, P4LC was found to be 17-fold
more effective than Pep-4 against E. coli and 82-fold more effec-
tive against B. cereus. In the highest salt concentrations tested
(μ = 167mM), P4LC was 20-fold more effective than free pep-
tide against E. coli and 10-fold more effective against B. cereus.
Meanwhile, EC50 values determined for Pep-4/LVFX were signif-
icantly lower than those of the conjugate in all conditions, with
the exception being the lowest ionic strength environment, where
the conjugate was significantly more effective against B. cereus.
These findings suggest that the enhanced activity of the conjugate
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relative to the free peptide is likely not due to the activity of
extracellular LVFX release. Our findings also suggest that there
was no synergistic enhancement of LVFX activity conferred by
coadministration of unmodified Pep-4 with free LVFX, as EC50
values for Pep-4/LVFX were in most cases not found to be
significantly lower than those of LVFX.
In order to gain insights into the antibacterial mechanisms of
P4LC and Pep-4, experiments were performed to investigate their
interactions with bacterial membranes. The fluorescent potentio-
metric probe DiSC(3)5 was used to assess the extent to which
P4LC, Pep-4, LVFX, and Pep-4/LVFX were able to induce bacte-
rial membrane depolarization. Compared to melittin, a known
pore-forming CAMP, P4LC induced moderate levels of depolar-
ization against both E. coli and B. cereus. Whereas, the depo-
larization affected by Pep-4 in E. coli and B. cereus was found
be approximately a half and a third, respectively, of that caused
by the conjugate. Similar to Pep-4, the Pep-4/LVFX combination
afforded minimal depolarization, with fluorescence curves found
not to be significantly different than those achieved using the free
peptide alone. Meanwhile, LVFX induced almost no detectable
depolarization. These results suggest that the covalently bound
fluoroquinolone enhanced the peptide’s ability to depolarize the
membranes of both E. coli and B. cereus relative to the free
peptide.
The membrane impermeable DNA-binding dye SYTOX Green
was used to further probe the interactions of P4LC and Pep-4
with bacterial membranes. In the case of E. coli, P4LC and Pep-
4 were observed to induce a moderate increase in fluorescence,
equivalent to approximately one fifth of that observed for the pos-
itive reference melittin. Yet, the conjugate induced a more rapid
increase in fluorescence than did the free peptide, a difference
that was verified through statistical analysis of regression curves
fit to the observed fluorescence kinetics data sets. In the case of
B. cereus, almost no detectable fluorescence increase was observed
for either P4LC or Pep-4. Meanwhile, the data sets acquired for
Pep-4/LVFX against both bacteria more closely resembled those
of Pep-4 than those of P4LC, an observation that was statistically
verified. Treatment with free LVFX was not found to produce an
increase in fluorescence against either bacterium. Taken together,
these results suggest that P4LC and Pep-4 both induce a mod-
erate degree of membrane perturbation against E. coli, but lit-
tle, if any, perturbation of B. cereus membranes. However, this
data also suggests that differences may exist in the membrane
disruption mechanisms employed by P4LC and Pep-4 against
E. coli.
It has been shown that alteration of peptide hydrophobicity
can influence CAMP interaction with membranes (Dathe and
Wieprecht, 1999; Podorieszach and Huttunen-Hennelly, 2010;
Lee et al., 2013a). Introduction of the moderately lipophilic LVFX
would be expected to effectively increase the hydrophobic char-
acter of the conjugate relative to the unmodified parent peptide.
Using a biphasic 1-octanol/phosphate partitioning system, we
found that the conjugate was approximately one order of mag-
nitude more hydrophobic than Pep-4 based on their respective
dissociation constants, D7.4 (Pep-4 logD7.4 = −2.57 vs. P4LC
logD7.4 = −1.65). This finding was consistent with the observa-
tion that the hydrophobicity of the free drug was approximately
one and a half orders of magnitude greater than that of free Pep-4
(LVFX logD7.4 = −1.05). The logD7.4 determined for LVFX that
is reported here is in agreement with previously reported val-
ues (Brillault et al., 2010; Lemaire et al., 2011). Interestingly, it
has been shown previously that increasing the hydrophobicity of
ten-residue peptides with similar sequences to Pep-4 resulted in
enhanced membrane interactions and reduced sensitivity to envi-
ronmental salt concentration (Bai et al., 2009). The enhanced
hydrophobicity conferred by the attached LVFX groups noted
here is likely a factor contributing to the more substantial mem-
brane interactions and increased salt resistance observed for the
conjugate relative to the free peptide.
CONCLUSION
In an effort to explore design parameters for engineering CAMP
conjugates with enhanced properties, a novel antimicrobial pep-
tide conjugate, P4LC, was generated by attaching multiple units
of the fluoroquinolone antibiotic LVFX to Pep-4, a ten residue
CAMP that presents multiple primary amino groups suitable for
drug attachment via acylation. Our studies revealed that while
P4LC displayed similar antibacterial effectiveness as the unmod-
ified parent peptide Pep-4 under low salt conditions, it was
substantially more potent under physiologically relevant high salt
conditions. This finding is significant because most CAMPs have
historically been found to lose antibacterial effectiveness in phys-
iological ionic strength environments, a fact which has presented
a challenge to the development of these peptides for therapeutic
applications. Our studies also suggest that the conjugate’s antibac-
terial potency is not due to extracellular release of free drug, as
evidenced by the results observed for unmodified Pep-4 coadmin-
isterd with free LVFX. Partitioning studies revealed that P4LC was
more hydrophobic than Pep-4, while depolarization studies indi-
cated that the conjugate was able to disrupt membrane integrity
to a greater degree than the free peptide. We propose that the con-
jugate’s observed increased hydrophobicity plays a role both in its
enhanced salt resistance and ability to depolarize bacterial mem-
branes. However, the influence that the LVFX groups have on the
performance of the conjugate may not solely be attributable to
the increased hydrophobicity. In our prior studies with Pep-4,
acetylation of its amino groups was found to decrease the effective
positive charge character of the peptide, which resulted in a signif-
icant reduction in potency under low salt conditions. In contrast,
acylation of Pep-4 with LVFX did not result in a loss of potency
under similar conditions. The superior performance of P4LC,
relative to acetylated Pep-4, could reflect contributions frommul-
tiple factors. Unlike acetyl groups, LVFX contains protonatable
nitrogens that could contribute to the overall cationic charac-
ter of the conjugate. Additionally, the affixed LVFX groups may
contribute some aspects of their inherent antimicrobial activ-
ity to that of the conjugate. Future efforts will focus on further
investigating factors contributing to the antibacterial properties
of P4LC and related conjugates. Parameters contributing to more
effectively capturing the inherent antibacterial potency of LVFX
will be of particular interest. Insights gained from studying the
performance and physicochemical properties of P4LC will pro-
vide valuable information that can be used in the design of
new conjugates incorporating different peptide scaffolds and a
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broader lexicon of auxiliary molecules, including antibiotics or
chemotherapeutics.
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